Table 1 Model input parameters

Dose

25 mg

75 mg

20 mg

50 mg

20 mg

Percentage of patients receiving double dose

22.1%

11.8%

23.0%

24.5%

0.0%

Remission

0.323 [20–22]

0.323*

0.284 [22]

0.289 [21]

0.323*

Recurrence

20% [25]

20% [25]

20% [25]

20% [25]

20% [25]

Suicide risk

20.35 [26]

20.35 [26]

20.35 [26]

20.35 [26]

20.35 [26]

Discontinuation

0.117 [20–23]

0.216 [20]

0.171 [22]

0.189 [21]

0.144 [23]

Discontinuation symptoms

0.00 [27]

0.20 [27]

0.00

0.00

0.07

Relapse

Survival function [28]

Survival function [28]

RR:0.513^§

RR:0.633^§

RR:0.531^§

Constipation

0.027 [20–23]

0.042 [20]

0.011 [22]

0.006 [21]

0.006 [23]

Dyspepsia

0.020 [20–23]

0.024 [20]

0.008 [22]

0.013 [21]

0.025 [23]

Diarrhoea

0.040 [20–23]

0.018 [20]

0.027 [22]

0.057 [21]

0.069 [23]

Nausea

0.066 [20–23]

0.226 [20]

0.114 [22]

0.044 [21]

0.138 [23]

Somnolence

0.035 [20–23]

0.048 [20]

0.034 [22]

0.013 [21]

0.038 [23]

Headache

0.111 [20–23]

0.119 [20]

0.114 [22]

0.101 [21]

0.144 [23]

Sexual Dysfunction

0.005 [20–23]

0.018 [29]

0.004 [22]

0.019 [21]

0.013 [23]

Sleep Disorder

0.007 [20–23]

0.024 [20]

0.019 [22]

0.019 [21]

0.025 [23]